

## NOVEL 1,3-DIALKYLUREA DERIVATIVES

Patent Number: ☐ EP0798291, A4, B1

Publication  
date: 1997-10-01

Inventor(s): FUJIMURA KEN-ICHI (JP); FUJITA YUKO (JP); SUHARA HIROSHI (JP); KAWASHIMA YOICHI (JP); MATSUMOTO HIROMI (JP); MIYAWAKI NOBUAKI (JP); YAMAMOTO NORIYOSHI (JP)

Applicant(s): SANTEN PHARMA CO LTD (JP)

Requested  
Patent: ☐ WO9618606

Application  
Number: EP19950939417 19951211

Priority Number  
(s): WO1995JP02539 19951211; JP19940310493 19941214

IPC  
Classification: C07C275/18; C07F9/09; A61K31/17; A61K31/195; A61K31/215; A61K31/175; A61K31/66

EC  
Classification: C07C275/24, C07F9/38A1, C07F9/40A1

Equivalents: DE69528197D, ☐ US5968980

Cited  
Documents:

---

### Abstract

The present invention relates to compounds represented by the formula  $\text{ÄIÜ}$  and salts thereof, wherein R<1> and R<5> each represents carboxyl, phosphonic or a derivative thereof; R<2> represents hydrogen, lower alkyl, (substituted) phenyl lower alkyl, lower alkoxy or (substituted) phenyl lower alkoxy; R<3> represents lower alkyl or (substituted) phenyl lower alkyl; and R<4> represents a group represented by the formula  $\text{ÄXIÜ}$ ,  $\text{ÄXIIÜ}$  or  $\text{ÄXIIIÜ}$ . The compounds of the present invention have endopeptidase 24.11 inhibitory activity and are useful for treating cardiovascular diseases such as heart failure and hypertension, renal diseases such as renal failure, gastroenteric disorders such as diarrhea and hyperchlorhydria, endocrine and metabolic diseases such as obesity, and autoimmune diseases such as rheumatic disease, and for mitigating myosalgia, migraine, etc.

---

Data supplied from the esp@cenet database - I2